Many in vivo and in vitro studies have suggested that the mechanism of radiotherapy sensitization by cetuximab in HNSCC or NSCLC is likely due to the inhibition of the PI3K/AKT pathway.32 This evidence concerns the gene AKT1 and head and neck squamous cell carcinoma.